Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines.

Caballero, M L; Quirce, S

Caballero, M L; Quirce, S.

Caballero ML; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.
Quirce S; Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.

J Investig Allergol Clin Immunol ; 31(1): 92-93, 2021 Feb 17.

Article in English | MEDLINE | ID: covidwho-1097522

Subject(s)

Anaphylaxis/chemically induced; COVID-19 Vaccines/adverse effects; Drug Hypersensitivity/etiology; Excipients/adverse effects; 2019-nCoV Vaccine mRNA-1273; Anaphylaxis/immunology; BNT162 Vaccine; COVID-19 Vaccines/chemistry; ChAdOx1 nCoV-19; Drug Compounding; Drug Hypersensitivity/immunology; Humans; Risk Assessment; Risk Factors

Keywords

Allergy; Anaphylaxis; COVID-19; Coronavirus; Excipient; Immediate drug hypersensitivity reaction; Pharmaceutical excipients; Vaccine

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Hypersensitivity / Excipients / COVID-19 Vaccines / Anaphylaxis Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Investig Allergol Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: Jiaci.0667

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google